PART I Item 1. B usiness. We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p...
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-06 | 2025-12-31 | 0001193125-26-095014 | EDGAR | 87K words |
| 2025-03-03 | 2024-12-31 | 0000950170-25-030414 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023062 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0000950170-23-005345 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007860 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001564590-21-010578 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-276003 | EDGAR | 21K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104588 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067513 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122817 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093343 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056295 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061551 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040153 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020100 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022920 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015767 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019071 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001193125-26-095094 | EDGAR | 2K words |
| 2025-11-12 | 0001193125-25-276000 | EDGAR | — |
| 2025-09-10 | 0001193125-25-199857 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104587 | EDGAR | — |
| 2025-06-09 | 0001193125-25-137497 | EDGAR | — |
| 2025-05-09 | 0000950170-25-067511 | EDGAR | — |
| 2025-03-03 | 0000950170-25-030407 | EDGAR | — |
| 2024-11-07 | 0000950170-24-122816 | EDGAR | — |
| 2024-08-08 | 0000950170-24-093345 | EDGAR | — |
| 2024-06-07 | 0001193125-24-156745 | EDGAR | — |
71 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001699382 |
| Ticker | PMVP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pmvpharma.com |
| Listed | 2020-09-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report